Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.50 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.50 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602430 | 0.85 | KDM4E (0.56) | CA12CA1CA2CA3CA4 | |
| SCHEMBL29404777 | 0.84 | LCK (0.62) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL23103 | 0.84 | LCK (0.62) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL21621 | 0.84 | KLKB1 (0.69) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL29365057 | 0.84 | KLKB1 (0.69) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL109609 | 0.83 | LCK (0.52) | CA2KLKB1CTSBMMP9DNMT1 | |
| SCHEMBL8479639 | 0.83 | CA12 (0.47) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31550006 | 0.83 | KLKB1 (0.74) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1401513 | 0.83 | ALDH1A1 (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL7227588 | 0.83 | EGFR (0.51) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6831106-B1 | Selective activity on cell proliferation and differentiation without displaying any hypercalcaemiant nature | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-14 | — | — | US | disclosed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | disclosed |
| EP-1235777-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | disclosed |
| EP-1235777-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2002-09-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001038303-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | CA12 4563/4885CA1 4376/4885CA2 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.